Acasti Pharma Inc (NASDAQ:ACST)’s share price shot up 6.1% during mid-day trading on Wednesday . The company traded as high as $0.72 and last traded at $0.70. 596,568 shares were traded during mid-day trading, an increase of 3% from the average session volume of 578,111 shares. The stock had previously closed at $0.66.

Separately, ValuEngine upgraded shares of Acasti Pharma from a “hold” rating to a “buy” rating in a research report on Wednesday, October 17th.

The stock has a market cap of $52.58 million, a PE ratio of -0.92 and a beta of 1.57. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.56 and a current ratio of 0.56.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Daily Political and is the property of of Daily Political. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at

Acasti Pharma Company Profile (NASDAQ:ACST)

Acasti Pharma Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia.

Further Reading: How Do You Calculate Return on Investment (ROI)?

Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with's FREE daily email newsletter.